Malignant pheochromocytoma: a review

Harari, Avital; Inabnet, William B.

doi:10.1016/j.amjsurg.2010.04.012

Cited by 93 publications

(88 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contrary to traditional belief that only 10 % of these tumours metastasise to nonchromaffin sites, such as lung, bone, liver or lymph nodes, higher prevalences of 26 and 35 % has been recently observed in malignant PCC and PGL respectively [1,2].…”

Section: Introductionmentioning

confidence: 84%

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Tan

Hussein²,

Saad

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 84%

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Tan

Hussein²,

Saad

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Five-year survival rates vary from 20% to 50% [1], with a significant heterogeneity among patients [11]. The majority of patients will succumb their disease [26], but long-term survival has been reported [27].…”

Section: Prognosismentioning

confidence: 98%

“…Therefore, the true rate of malignant PCC cannot be defined as tumorassociated criteria are not available. Despite these limitations, the overall rate of malignant PCCs is traditionally cited to be roughly 10% [3,11], with a wide range between 2.4% and 50% depending on the definition of malignancy and patient's selection [4,5,[12][13][14][15]. Up to 5-20% of sympathetic PGLs are considered as being malignant [14,16,17].…”

Section: Malignancymentioning

confidence: 99%

Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

Gimm

DeMicco

Perren

et al. 2011

Langenbecks Arch Surg

View full text Add to dashboard Cite

Due to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.

show abstract

“…The remaining neoplasms were defined as intermediately aggressive, roughly corresponding to the present grades 1 and 2 neuroendocrine tumors. In tumor groups where the stratification based on the morphological codes was less forward, we searched the literature for behavior and patient survival before classification into one of the aggressiveness groups [26,27,28,29,30,31,32]. …”

Section: Methodsmentioning

confidence: 99%

Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010

et al. 2015

View full text Add to dashboard Cite

Background: Epidemiological studies show an increasing trend in the incidence of neuroendocrine neoplasms (NENs). A significant number of NENs occur in less common primary sites, but they are often excluded from the population-based studies. We studied the incidence trends of all NENs in Norway according to different primary sites. Materials and Methods: Our analyses were based on cancer cases diagnosed between 1993 and 2010 and reported to the national population-based Cancer Registry of Norway. A total of 65 morphological codes were identified as neuroendocrine and stratified into 3 different groups of aggressiveness: low, intermediate and high. Results: We identified 16,075 NENs of which 49.5% were in women. The median age at diagnosis was 65 years. The most common primary sites were the lung (48.1%) and the gastroenteropancreatic system (18.0%). Stage at diagnosis was local in 40.4% of the cases, regional in 17.5% and distant in 42.1%. The stage distribution was stable throughout the study period. The age-standardized (European) incidence rate (per 100,000 person-years) increased from 13.3 in 1993 to 21.3 in 2010 with an estimated annual increase of 5.1% in women and 2.1% in men. The increase was most pronounced for tumors of intermediate aggressiveness from 3.3 in 1993 to 7.3 in 2010. The largest annual increases were estimated for the adrenal gland (8.8%), the pancreas (6.9%) and the lungs (6.1%). Conclusion: The incidence of NENs increased. Most primary tumors were found in the lungs or in the gastroenteropancreatic system. The increase in the incidence differed according to the primary site, gender and tumor aggressiveness.

show abstract

Malignant pheochromocytoma: a review

Cited by 93 publications

References 43 publications

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010

Contact Info

Product

Resources

About